C. Parker

发表

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

I. Tannock, M. Rubin, A. Chinnaiyan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols

Matthew R. Sydes, Noel W. Clarke, Lindsey Masters, 2019, Trials.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

R. Laing, M. Parmar, M. Sydes, 2016, The Lancet.

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

N. James, L. Billingham, D. McLaren, 2016, JAMA oncology.

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. Parmar, M. Sydes, D. Dearnaley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

M. Parmar, M. Sydes, D. Dearnaley, 2014, European urology.

Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

N. James, L. Billingham, D. McLaren, 2017, BJU international.

Costeffectiveness of zoledronic acid and strontium89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castraterefractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

S. Beesley, A. Birtle, S. Collins, 2022 .

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

M. Kattan, C. Parker, S. Nilsson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

D. Dearnaley, C. Parker, J. Bono, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial

D. Dearnaley, V. Khoo, J. Staffurth, 2022, International journal of radiation oncology, biology, physics.

Cancer Drugs Fund requires further reform

D. Spiegelhalter, L. Smeeth, J. Sekhon, 2016, British Medical Journal.

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

M. Parmar, M. Sydes, D. Dearnaley, 2016, JAMA oncology.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

M. Sydes, D. Dearnaley, C. Parker, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data

M. Sydes, D. Dearnaley, N. James, 2022, PloS one.

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

N. James, A. Cross, Chris Parker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

N. James, L. Billingham, D. McLaren, 2016, Health technology assessment.

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) with

S. Beesley, A. Stanley, S. Hussain, 2018 .

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer

L. Billingham, D. McLaren, S. Beesley, 2017 .

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer

N. James, L. Billingham, D. McLaren, 2016 .

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

H. Beltran, M. Matikainen, N. Fossati, 2024, European urology.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .